Bristol-Myers Squibb and PsiOxus Therapeutics Declare Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev

Bristol-Psioxus

June 30, 2016

Bristol-Myers Squibb Company and PsiOxus Therapeutics, Ltd. have announced an exclusive clinical collaboration agreement for evaluating the tolerability, safety, and preliminary efficacy of Bristol-Myers Squibb’s Immuno-Oncology (I-O) agent Opdivo (nivolumab), in combination with PsiOxus’ enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, to treat a range of tumor types in late-stage cancer patients.

“This collaboration continues to expand our clinical development of Opdivo and explores how oncolytic viruses may provide a complementary mechanism to address tumors that are resistant to I-O therapy, We are excited to partner with PsiOxus to evaluate the combination of Opdivo and enadenotucirev to accelerate our understanding of its potential as a new therapeutic option for cancer patients,” said Jean Viallet, M.D., Global Clinical Research Lead, Oncology, Bristol-Myers Squibb.

As stated by John Beadle, M.D., Chief Executive Officer, PsiOxus: “We are delighted to collaborate with Bristol-Myers Squibb and to investigate enadenotucirev with Opdivo in several tumor types. They are our ideal partner since we share a common vision of exploring novel combinations such as enadenotucirev and Opdivo to expand the range of patients who potentially respond favorably to checkpoint inhibitor therapy.”

 

Bristol-Myers Squibb and PsiOxus Therapeutics Declare Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev last edit: 2016-07-11T17:59:21+00:00 da Luca

Leave a Reply

*The views and opinions expressed on IgeaHub belong to the authors only. They do not represent the views or opinions of any company or organization.

Follow Us

Join us

All rights reserved. Terms of use and Privacy Policy

Design by PT Webmaster

%d bloggers like this:
Skip to toolbar